TY - JOUR
T1 - Clinical applications of hallucinogens
T2 - A review
AU - Garcia-Romeu, Albert
AU - Kersgaard, Brennan
AU - Addy, Peter H.
N1 - Funding Information:
Support for Dr. Garcia-Romeu was provided by National Institute on Drug Abuse Grant T32DA07209 and the Heffter Research Institute. The funding sources had no role other than financial support. We thank Toni White, B.A., for her meticulous work in organizing and editing the references in this article. All authors contributed in a significant way to the manuscript. All authors have read and approved the final manuscript
Publisher Copyright:
© 2016 American Psychological Association.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound alterations of consciousness, involving acute changes in somatic, perceptual, cognitive, and affective processes. Such effects likely contribute to their recreational use. However, a growing body of evidence indicates that these drugs may have therapeutic applications beyond their potential for abuse. This review will present data on several classes of hallucinogens with a particular focus on psychedelics, entactogens, and dissociatives, for which clinical utility has been most extensively documented. Information on each class is presented in turn, tracing relevant historical insights, highlighting similarities and differences between the classes from the molecular to the behavioral level, and presenting the most up-to-date information on clinically oriented research with these substances, with important ramifications for their potential therapeutic value.
AB - Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound alterations of consciousness, involving acute changes in somatic, perceptual, cognitive, and affective processes. Such effects likely contribute to their recreational use. However, a growing body of evidence indicates that these drugs may have therapeutic applications beyond their potential for abuse. This review will present data on several classes of hallucinogens with a particular focus on psychedelics, entactogens, and dissociatives, for which clinical utility has been most extensively documented. Information on each class is presented in turn, tracing relevant historical insights, highlighting similarities and differences between the classes from the molecular to the behavioral level, and presenting the most up-to-date information on clinically oriented research with these substances, with important ramifications for their potential therapeutic value.
KW - Club drugs
KW - Dissociative
KW - Drug policy
KW - Hallucinogen
KW - Psychedelic
UR - http://www.scopus.com/inward/record.url?scp=84979912950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979912950&partnerID=8YFLogxK
U2 - 10.1037/pha0000084
DO - 10.1037/pha0000084
M3 - Article
C2 - 27454674
AN - SCOPUS:84979912950
SN - 1064-1297
VL - 24
SP - 229
EP - 268
JO - Experimental and Clinical Psychopharmacology
JF - Experimental and Clinical Psychopharmacology
IS - 4
ER -